Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
Plain-language summary
This trial is testing ONO-4685 (an investigational intravenous drug) for patients with various types of peripheral T-cell lymphoma (PTCL) whose disease has come back or stopped responding to prior treatment. This is a Phase 1 trial, which means researchers are finding the right dose and this is among the earliest testing in patients. The study looks at both safety and how well the treatment controls the lymphoma. This trial is available at 20 locations in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 18 Years or older
- Lymphoma came back or did not respond to prior treatment
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
ONO-4685 (DRUG): ONO-4685 is administered by IV infusion. The administration of ONO-4685 will be continued until disease progression or unacceptable toxicity is observed
ONO-4685
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details